Cargando…

Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases

BACKGROUND: Several studies have shown that the immunophenotype of distant breast cancer metastases may differ significantly from that of the primary tumor, especially with regard to differences in the level of hormone receptor protein expression, a process known as receptor conversion. This study a...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiwa, Laura S, van Diest, Paul J, Hoefnagel, Laurien D, Wesseling, Jelle, Wesseling, Pieter, Moelans, Cathy B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247109/
https://www.ncbi.nlm.nih.gov/pubmed/25417118
http://dx.doi.org/10.1186/1471-2407-14-864
_version_ 1782346587407646720
author Jiwa, Laura S
van Diest, Paul J
Hoefnagel, Laurien D
Wesseling, Jelle
Wesseling, Pieter
Moelans, Cathy B
author_facet Jiwa, Laura S
van Diest, Paul J
Hoefnagel, Laurien D
Wesseling, Jelle
Wesseling, Pieter
Moelans, Cathy B
author_sort Jiwa, Laura S
collection PubMed
description BACKGROUND: Several studies have shown that the immunophenotype of distant breast cancer metastases may differ significantly from that of the primary tumor, especially with regard to differences in the level of hormone receptor protein expression, a process known as receptor conversion. This study aimed to compare expression levels of several membrane proteins between primary breast tumors and their corresponding distant metastases in view of their potential applicability for molecular imaging and drug targeting. METHODS: Expression of Claudin-4, EGFR, CAIX, GLUT-1 and IGF1R was assessed by immunohistochemistry on tissue microarrays composed of 97 paired primary breast tumors and their distant (non-bone) metastases. RESULTS: In both the primary cancers and the metastases, Claudin-4 was most frequently expressed, followed by GLUT-1, CAIX and EGFR. From primary breast cancers to their distant metastases there was positive to negative conversion, e.g. protein expression in the primary tumor with no expression in its paired metastasis, in 6%, 19%, 12%, 38%, and 0% for Claudin-4 (n.s), GLUT-1 (n.s), CAIX (n.s), EGFR (n.s) and IGF1R (n.s) respectively. Negative to positive conversion was seen in 65%, 47%, 43%, 9% and 0% of cases for Claudin-4 (p = 0.049), GLUT-1 (p = 0.024), CAIX (p = 0.002), EGFR (n.s.) and IGF1R (n.s.) respectively. Negative to positive conversion of Claudin-4 in the metastasis was significantly associated with tumor size (p = 0.015), negative to positive conversion of EGFR with negative PR status (p = 0.046) and high MAI (p = 0.047) and GLUT-1 negative to positive conversion with (neo)adjuvant chemotherapy (p = 0.039) and time to metastasis formation (p = 0.034). CAIX and GLUT-1 expression in the primary tumor were significantly associated with high MAI (p = 0.008 and p = 0.038 respectively). CONCLUSION: Claudin-4 is frequently expressed in primary breast cancers but especially in their metastases and is thereby an attractive membrane bound molecular imaging and drug target. Conversion in expression of the studied proteins from the primary tumor to metastases was fairly frequent, except for IGF1R, implying that the expression status of metastases cannot always be reliably predicted from the primary tumor, thereby necessitating biopsy for reliable assessment.
format Online
Article
Text
id pubmed-4247109
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42471092014-11-29 Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases Jiwa, Laura S van Diest, Paul J Hoefnagel, Laurien D Wesseling, Jelle Wesseling, Pieter Moelans, Cathy B BMC Cancer Research Article BACKGROUND: Several studies have shown that the immunophenotype of distant breast cancer metastases may differ significantly from that of the primary tumor, especially with regard to differences in the level of hormone receptor protein expression, a process known as receptor conversion. This study aimed to compare expression levels of several membrane proteins between primary breast tumors and their corresponding distant metastases in view of their potential applicability for molecular imaging and drug targeting. METHODS: Expression of Claudin-4, EGFR, CAIX, GLUT-1 and IGF1R was assessed by immunohistochemistry on tissue microarrays composed of 97 paired primary breast tumors and their distant (non-bone) metastases. RESULTS: In both the primary cancers and the metastases, Claudin-4 was most frequently expressed, followed by GLUT-1, CAIX and EGFR. From primary breast cancers to their distant metastases there was positive to negative conversion, e.g. protein expression in the primary tumor with no expression in its paired metastasis, in 6%, 19%, 12%, 38%, and 0% for Claudin-4 (n.s), GLUT-1 (n.s), CAIX (n.s), EGFR (n.s) and IGF1R (n.s) respectively. Negative to positive conversion was seen in 65%, 47%, 43%, 9% and 0% of cases for Claudin-4 (p = 0.049), GLUT-1 (p = 0.024), CAIX (p = 0.002), EGFR (n.s.) and IGF1R (n.s.) respectively. Negative to positive conversion of Claudin-4 in the metastasis was significantly associated with tumor size (p = 0.015), negative to positive conversion of EGFR with negative PR status (p = 0.046) and high MAI (p = 0.047) and GLUT-1 negative to positive conversion with (neo)adjuvant chemotherapy (p = 0.039) and time to metastasis formation (p = 0.034). CAIX and GLUT-1 expression in the primary tumor were significantly associated with high MAI (p = 0.008 and p = 0.038 respectively). CONCLUSION: Claudin-4 is frequently expressed in primary breast cancers but especially in their metastases and is thereby an attractive membrane bound molecular imaging and drug target. Conversion in expression of the studied proteins from the primary tumor to metastases was fairly frequent, except for IGF1R, implying that the expression status of metastases cannot always be reliably predicted from the primary tumor, thereby necessitating biopsy for reliable assessment. BioMed Central 2014-11-22 /pmc/articles/PMC4247109/ /pubmed/25417118 http://dx.doi.org/10.1186/1471-2407-14-864 Text en © Jiwa et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Jiwa, Laura S
van Diest, Paul J
Hoefnagel, Laurien D
Wesseling, Jelle
Wesseling, Pieter
Moelans, Cathy B
Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases
title Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases
title_full Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases
title_fullStr Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases
title_full_unstemmed Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases
title_short Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases
title_sort upregulation of claudin-4, caix and glut-1 in distant breast cancer metastases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247109/
https://www.ncbi.nlm.nih.gov/pubmed/25417118
http://dx.doi.org/10.1186/1471-2407-14-864
work_keys_str_mv AT jiwalauras upregulationofclaudin4caixandglut1indistantbreastcancermetastases
AT vandiestpaulj upregulationofclaudin4caixandglut1indistantbreastcancermetastases
AT hoefnagellauriend upregulationofclaudin4caixandglut1indistantbreastcancermetastases
AT wesselingjelle upregulationofclaudin4caixandglut1indistantbreastcancermetastases
AT wesselingpieter upregulationofclaudin4caixandglut1indistantbreastcancermetastases
AT upregulationofclaudin4caixandglut1indistantbreastcancermetastases
AT moelanscathyb upregulationofclaudin4caixandglut1indistantbreastcancermetastases